Clinical trials: Menopausal
Neoplasms, Breast Neoplasms
Study of Anastrozole +/- AZD8931 in Postmenopausal Women With Endocrine Therapy Naive Breast Cancer
The main purpose of this study is to compare progression free survival in patients treated with AZD8931 given in combination with anastrozole versus anastrozole alone.
- Conditions
- Neoplasms, Breast Neoplasms, Breast Cancer
- Trial name
- MINT (NCT01151215)
- Testing
- AZD8931, anastrozole
- Where
- 60 sites in United States, Brazil and 16 more
- Volunteers
- 482 people
- Sponsor
- AstraZeneca
Vasomotor Symptoms Associated With Menopause, Hot Flashes
A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the Menopause (OASIS-2)
Researchers are looking for a better way to treat women who have hot flashes after women have been through the menopause. Hot flashes are caused by the hormonal changes that happen when a woman's body has been through the…
- Trial name
- NCT05099159
- Testing
- Elinzanetant (BAY3427080)
- Where
- 113 sites in United States, Canada and 10 more
- Volunteers
- 400 people
- Sponsor
- Bayer
Healthy, Premature Ovarian Failure
Feasibility Study for Development of an Early Test for Ovarian Failure
This purpose of this study is to gain information about normal ovarian function that will be useful in developing a test for early detection of ovarian failure.
- Trial name
- NCT00006156
- Testing
- Control, Drug: FSH
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Metastatic Breast Cancer
Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)
The study is a randomized, double blind, placebo controlled, Phase 3 clinical trial with the primary objective of demonstrating the superiority of palbociclib in combination with fulvestrant (Faslodex®) over fulvestrant alone in…
- Trial name
- NCT01942135
- Testing
- Palbociclib, Fulvestrant
- Where
- 247 sites in United States, Australia and 15 more
- Volunteers
- 521 people
- Sponsor
- Pfizer
Advanced ER-Positive HER2-Negative Breast Cancer
A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer
This study is randomized, open-label, parallel-group, multicentre Phase 2 study aimed to compare the efficacy and safety of oral AZD9833 versus intramuscular (IM) fulvestrant in women with advanced breast cancer.
- Trial name
- SERENA-2 (NCT04214288)
- Testing
- AZD9833, Fulvestrant
- Where
- 85 sites in United States, Belgium and 14 more
- Volunteers
- 240 people
- Sponsor
- AstraZeneca
Combat Disorders
Prospective Study of Veteran Health in Previously Deployed Soldiers
Background: Previous deployments like that to the Persian Gulf in 1991 produced veterans with post-deployment symptom-based health problems with no medical explanation.
- Trial name
- NCT00285246
- Where
- 2 sites in United States
- Volunteers
- 838 people, healthy volunteers welcome
- Sponsor
- US Department of Veterans Affairs
Insomnia, Metabolic Health
Treating Insomnia and Improving Metabolic Health in Midlife Women With Insomnia
The aim of this study is to determine if suvorexant can help treat the severity of insomnia and improve metabolic health in midlife women who had both insomnia and indicators of metabolic syndrome.
- Conditions
- Insomnia, Metabolic Health, Menopause
- Trial name
- NCT05593653
- Testing
- Suvorexant
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Brigham and Women's Hospital
Breast Cancer, Cancer of the Breast
Comparing Letrozole Given Alone to Letrozole Given With Avastin in Post-Menopausal Women Breast Cancer
This purpose of this trial is to show that the combination of Avastin and hormone therapy should be more effective than hormone therapy alone for the treatment of breast cancer.
- Conditions
- Breast Cancer, Cancer of the Breast, Breast Neoplasm
- Trial name
- NCT00530868
- Testing
- Letrozole (Femara), Letrozole; Avastin
- Where
- 7 sites in United States
- Volunteers
- 75 people
- Sponsor
- University of Alabama at Birmingham
Insomnia
Efficacy of Suvorexant in the Treatment of Hot Flash-associated Insomnia
The aim of this study is to determine the effect of suvorexant on insomnia symptoms in peri- and postmenopausal women who are experiencing sleep difficulties related to nighttime hot flashes.
- Trial name
- NCT03034018
- Testing
- suvorexant
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Brigham and Women's Hospital
Menopause, Fracture
Forteo for the Treatment of Unexplained Osteoporosis in Premenopausal Women
Idiopathic osteoporosis (IOP) is an uncommon disorder in which otherwise healthy young individuals sustain one or more low-trauma fractures.
- Conditions
- Menopause, Fracture, Osteoporosis
- Trial name
- IOPForteo (NCT00697463)
- Testing
- Teriparatide (PTH 1-34)
- Where
- 2 sites in United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Columbia University
Hot Flashes, Menopause
MsFLASH-01: Escitalopram for Menopausal Symptoms in Midlife Women
The purpose of this study is to test whether a medication reduces the number, severity and bothersomeness of menopausal hot flashes. Escitalopram (also called Lexapro®) is a selective serotonin reuptake inhibitor (SSRI).
- Conditions
- Hot Flashes, Menopause, Vasomotor Symptoms
- Trial name
- NCT00894543
- Testing
- Escitalopram
- Where
- 5 sites in United States
- Volunteers
- 205 people, healthy volunteers welcome
- Sponsor
- Fred Hutchinson Cancer Center
Post Menopausal Osteoporosis
Phase 2 Study of BA058 (Abaloparatide) Transdermal Delivery in Postmenopausal Women With Osteoporosis
To determine the clinical safety and efficacy of abaloparatide transdermal in otherwise healthy postmenopausal women with osteoporosis as assessed by changes in bone mineral density (BMD) and serum markers of bone metabolism when…
- Trial name
- NCT01674621
- Testing
- Abaloparatide Transdermal (50 mcg), Abaloparatide Transdermal (100 mcg), Abaloparatide Transdermal (150 mcg)
- Where
- 9 sites in United States, Denmark and 2 more
- Volunteers
- 250 people
- Sponsor
- Radius Health, Inc.
Menopause, Vasomotor Symptoms
Dose-Finding Safety and Efficacy Trial of Org50081 (Esmirtazapine) in the Treatment of Vasomotor Symptoms (46101/P06459/MK-8265-012)
The most direct treatment of vasomotor symptions (hot flushes) may be by means of 5-HT2A receptor antagonist. Mirtazapine is a potent blocker of 5-HT2A receptors and was found to be effective in reducing the number and intensity…
- Trial name
- NCT00560833
- Testing
- esmirtazapine
- Volunteers
- 943 people
- Sponsor
- Merck Sharp & Dohme LLC
Metastatic Breast Cancer
Phase I/II Trial of Letrozole and Sorafenib in Post-Menopausal Hormone-Receptor + Breast Cancer
Letrozole is an aromatase inhibitor that is approved in the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer.
- Trial name
- NCT00634634
- Testing
- Sorafenib, Letrozole
- Where
- 4 sites in United States
- Volunteers
- 52 people
- Sponsor
- Rutgers, The State University of New Jersey
Vaginal Atrophy
DHEA Against Vaginal Atrophy - Safety Study of 12 Months
The purpose of this Phase III trial is to assess the long-term safety of intravaginal dehydroepiandrosterone (DHEA) in non-hysterectomized postmenopausal women with vaginal atrophy aged 40 to 75 years.
- Trial name
- NCT01256671
- Testing
- DHEA
- Where
- 41 sites in United States, Canada
- Volunteers
- 530 people
- Sponsor
- EndoCeutics Inc.
Osteoporosis
Effects of Zoledronic Acid and Raloxifene on Bone Turnover Markers in Postmenopausal Women With Low Bone Mineral Density
This study will compare the effects of Zoledronic acid and Raloxifene in reducing bone turnover markers in postmenopausal women with low bone mineral density over 6 months.
- Trial name
- NCT00431444
- Testing
- Raloxifene, Zoledronic acid
- Where
- 17 sites in United States
- Volunteers
- 110 people
- Sponsor
- Novartis
Comparing Bioavailability When Makena® is Administered in Healthy Post-menopausal Women
Comparing Bioavailability When Preservative-free Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) is Administered as an Intramuscular Manual Injection or as a Subcutaneous Injection Using an Auto-injector in Healthy Post-menopausal Women
To demonstrate that a single dose of Makena® delivered SQ via auto-injector has comparable bioavailability to a single IM injection of Makena®.
- Trial name
- NCT02940522
- Testing
- Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)
- Where
- 5 sites in United States
- Volunteers
- 122 people, healthy volunteers welcome
- Sponsor
- AMAG Pharmaceuticals, Inc.
Contraception, Menopause
Study Conducted to Further Understand the Elimination Pathways, Metabolite Profile and PK Profile of 14C-estetrol
This study is being conducted to further understand the elimination pathways, metabolite profile and pharmacokinetic (PK) profile of carbon 14 labelled estetrol ([14C] estetrol).
- Trial name
- NCT02720224
- Testing
- Estetrol
- Where
- United Kingdom
- Volunteers
- 6 people
- Sponsor
- Estetra
Uterine Fibroids
Pharmacokinetics, Safety and Efficacy Study of Proellex in Pre-menopausal Women With Symptomatic Uterine Fibroids
PK of 25 mg and 50 mg Proellex® administered once daily (QD) over a 4-month period.
- Trial name
- NCT00683917
- Testing
- Proellex 25 mg, Proellex 50 mg, Lupron Depot
- Where
- 4 sites in United States, Mexico
- Volunteers
- 10 people
- Sponsor
- Repros Therapeutics Inc.
Post Menopausal Breast Cancer
Study in Post-menopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer
This international, multi-center, open-label, single-arm study evaluated the safety and tolerability profile of everolimus in post-menopausal women with HR positive, HER2 negative locally advanced or metastatic breast cancer…
- Trial name
- EVEREXES (NCT03176238)
- Testing
- everolimus, exemestane
- Where
- 55 sites in Australia, India and 11 more
- Volunteers
- 235 people
- Sponsor
- Novartis Pharmaceuticals